Interferon-alpha inhibits proliferation and induces apoptosis of Merkel cell carcinoma in vitro

Cancer Investigation

Volumn 26, Issue 6, 2008, Pages 562-568

  Krasagakis, Konstantin ^a   Kruger Krasagakis, Sabine ^a   Tzanakakis, George N ^a   Darivianaki, Katherine ^a   Stathopoulos, Efstathios N ^a   Tosca, Androniki D ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Apoptosis; Interferon alpha; Merkel cell carcinoma; Proliferation

Indexed keywords

ALPHA INTERFERON; CASPASE 3; DNA; INTERLEUKIN 2; KI 67 ANTIGEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; DNA SYNTHESIS; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MERKEL CELL TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, MERKEL CELL; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DNA BREAKS; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERFERON ALFA-2A; INTERFERON-ALPHA; KI-67 ANTIGEN; MERKEL CELLS; RECEPTOR, INTERFERON ALPHA-BETA; SKIN NEOPLASMS; TIME FACTORS;

EID: 46349090607     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701816477     Document Type: Article

References (35)

1. Hitchcock, C.L.; Bland, K.I.; Laney, R.G.; et al. Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg 1988, 207, 201-207.
2. Krasagakis, K.; Tosca, A.D. Overview of Merkel cell carcinoma and recent advances in research. Int J Dermatol 2003, 42, 669-676.
3. Poulsen, M. Merkel-cell carcinoma of the skin. Lancet Oncol 2004, 5, 593-599.
4. Voog, E.; Biron, P.; Martin, J.P.; Blay, J.Y. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 1999, 85, 2589-2595.
5. Tai, P.T.; Yu, E.; Winquist, E.; et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 2000, 18, 2493-2499.
6. Durand, J.M.; Weiller, C.; Richard, M.A.; et al. Treatment of Merkel cell tumor with interferon-alpha-2b. Br J Dermatol 1991, 124, 509.
7. Bajetta, E.; Zilembo, N.; Di Bartolomeo, M.; et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 1993, 72, 3099-3105.
8. Krasagakis, K.; Almond-Roesler, B.; Zouboulis, C.C.; et al. Merkel cell carcinoma: report of ten cases with emphasis on clinical course, treatment, and in vitro drug sensitivity. J Am Acad Dermatol 1997, 36, 727-732.
9. Garbe, C.; Krasagakis, K. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 1993, 100, 239s-244s.
10. Fishman, M.; Seigne, J. Immunotherapy of metastatic renal cell cancer. Cancer Control 2002, 9, 293-304.
11. Tagliaferri, P.; Caraglia, M.; Budillon, A.; et al. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother 2005, 54, 1-10.
12. Krasagakis, K.; Almond-Roesler, B., Geilen, C.; et al. Growth and characterization of a cell line from a human primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma) in culture and as xenograft. J Cell Physiol 2001, 187, 386-391.
13. Krüger-Krasagakes, S.; Krasagakis, K.; Garbe, C.; et al. Expression of interleukin 10 in human melanoma. Br J Cancer 1994, 70, 1182-1185.
14. Yamamura, M.; Uyemura, K.; Deans, R.J.; et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991, 254, 277-279.
15. Gjorret, J.O.; Knijn, H.M.; Dieleman, S.J.; et al. Chronology of apoptosis in bovine embryos produced in vivo and in vitro. Biol Reprod 2003, 69, 1193-1200.
16. Genot, E.; Billard, C.; Sigaux, F.; et al. Proliferative response of hairy cells to B cell growth factor (BCGF): in vivo inhibition by interferon-alpha and in vitro effects of interferon-alpha, -beta, and -gamma. Leukemia 1987, 1, 590-596.
17. Oshima, K.; Yanase, N.; Ibukiyama, C.; et al. Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells. Cytokine 2001, 14, 193-201.
18. Certa, U.; Wilhelm-Seiler, M.; Foser, S.; et al. Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha. Gene 2003, 315, 79-86.
19. Krasagakis, K.; Garbe, C.; Krüger, S.; Orfanos, C.E. Effects of interferons on cultured human melanocytes in vitro: interferon- beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 1991, 97, 364-372.
20. Khan, M.A.; Tolleson, W.H.; Gangemi, J.D.; Pirisi, L. Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons. J Virol 1993, 67, 3396-3403.
21. Brodowicz, T.; Wiltschke, C.; Kandioler-Eckersberger, D.; et al. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br J Cancer 1999, 80, 1350-1358.
22. Gomez, D.; Reich, N.C. Stimulation of primary human endothelial cell proliferation by IFN. J Immunol 2003, 170, 5373-5381.
23. Taylor, K.L.; Oates, R.K.; Grane, R.; et al. IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas. J Interferon Cytokine Res 2006, 26, 353-361.
24. Sangfelt, O.; Erickson, S.; Castro, J.; et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999, 18, 2798-2810.
25. Scott, R.J.; Hall, P.A.; Haldane, J.S.; et al. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 1991, 165, 173-178.
26. Schlüter, C.; Duchrow, M.; Wohlenberg, C.; et al. The cell proliferation-associated antigen of antibody Ki-67: A very large, ubiquitus nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993, 123, 513-522.
27. Koljonen, V.; Tukiainen, E.; Haglund, C.; Böhling, C. Proliferative activity detected by Ki67 correlates with poor outcome in Merkel cell carcinoma. Histopathol 2006, 49, 551-553.
28. Gamero, A.M.; Potla, R.; Sakamoto, S.; et al. Type I interferons activate apoptosis in a Jurkat cell variant by caspase-dependent and independent mechanisms. Cell Signal 2006, 18, 1299-1308.
29. Thyrell, L.; Erickson, S.; Zhivotovsky, B.; et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002, 21, 1251-1262.
30. Kirkwood, J.M.; Strawderman, M.H.; Ernstoff, M.S.; et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14, 7-17.
31. Gutterman, J.U.; Fine, S.; Quesada, J.; et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982, 96, 549-556.
32. Kern, P.; Meigel, W.; Racz, P.; et al. Interferon alpha in the treatment of AIDS-associated Kaposi's sarcoma. Onkologie 1987, 10, 50-52.
33. Buzaid, A.C.; Robertone, A.; Kisala, C.; Salmon, S.E. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol 1987, 5, 1083-1089.
34. Ludwig, C.U.; Ludwig-Hagemann, R.; Obrist, R.; et al. Improved tolerance of interferon alpha-2a by continuous subcutaneous infusion. Onkologie 1990, 13, 117-122.
35. Talpaz, M.; Rakhit, A.; Rittweger, K.; et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 2005, 11, 6247-6255.